Present address: C. J. Turtle, Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma
Version of Record online: 22 AUG 2008
© 2008 Mater Medical Research Institute. Journal Compilation © 2008 Blackwell Publishing Ltd
British Journal of Haematology
Volume 143, Issue 3, pages 374–377, November 2008
How to Cite
Vari, F., Munster, D. J., Hsu, J. L., Rossetti, T. R., Mahler, S. M., Gray, P. P., Turtle, C. J., Prue, R. L. and Hart, D. N. J. (2008), Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma. British Journal of Haematology, 143: 374–377. doi: 10.1111/j.1365-2141.2008.07346.x
- Issue online: 14 OCT 2008
- Version of Record online: 22 AUG 2008
- Received 20 April 2008; accepted for publication 20 June 2008
- blood dendritic cells;
- immunomagnetic separation;
- cancer vaccine;
- multiple myeloma
Therapeutic vaccination combined with new drugs may cure multiple myeloma (MM). We have developed a bio-process to purify CMRF-56 monoclonal antibody (mAb) and a standard operating procedure to immunoselect blood dendritic cells (BDC). Leucopheresed mononuclear cells were cultured overnight, labelled with CMRF-56 mAb and BDC prepared using a clinical scale immunoselection system. The mean BDC yield from healthy donors was 48% (n = 6, purity 28%). Preparations from MM patients (n = 6, yield 47%, purity 35%) primed cytotoxic T lymphocytes (CTL) to clinically relevant MM antigens. This procedure can be performed readily by clinical cell manufacturing units to facilitate BDC vaccination studies.